Prothena Co.

Prothena has appointed Annie Kingston as chief strategy officer with immediate effect; Michael Isaacs will become general counsel and corporate secretary in June following the departure of Michael Malecek. Both will join the leadership team and report to CEO Gene Kinney; Kingston will lead growth strategy, and Isaacs will head the legal department. Prothena is a late-stage clinical biotech company with programs targeting Parkinson’s, ATTR amyloidosis, Alzheimer’s and ALS and a market capitalization of about $566 million. » More on de.investing.com

Prothena’s board has approved a repurchase program to buy up to $100 million of its common stock. As of December 31, 2025, the biotech had cash of $308.4 million and no debt; without buybacks Prothena expects to have about $255 million in cash at the end of 2026. Potential clinical milestone payments of up to $105 million from partners (including Novo Nordisk and Bristol Myers Squibb) are not included in this forecast. The program runs through December 31, 2026, can be suspended at any time, and is intended to be executed in a market‑compliant manner under Rule 10b‑18 or via 10b5‑1 plans. » More on de.investing.com

Paula Cobb is stepping down from Prothena’s board after six years to assume the role of chief operating officer (COO) at Manifold Bio. After her departure, Prothena’s board will consist of eight members. Prothena is a late-stage clinical biotechnology company with programs for ATTR amyloidosis, Alzheimer’s and Parkinson’s; analysts have recently cited price targets between $8 and $36. » More on de.investing.com